53 related articles for article (PubMed ID: 8031063)
1. Biofilm Development by
Akir A; Senhaji-Kacha A; Muñoz-Egea MC; Esteban J; Aguilera-Correa JJ
Antibiotics (Basel); 2024 Mar; 13(3):. PubMed ID: 38534698
[TBL] [Abstract][Full Text] [Related]
2. A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.
Kaya F; Ernest JP; LoMauro K; Gengenbacher M; Madani A; Aragaw WW; Zimmerman MD; Sarathy JP; Alvarez N; Daudelin I; Wang H; Lanni F; Weiner DM; Via LE; Barry CE; Olivier KN; Dick T; Podell BK; Savic RM; Dartois V
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0221221. PubMed ID: 35099272
[TBL] [Abstract][Full Text] [Related]
3. Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update".
Drwiega EN; Rodvold KA
Clin Pharmacokinet; 2022 Feb; 61(2):337-338. PubMed ID: 34982408
[No Abstract] [Full Text] [Related]
4. Genetic Determinants of Intrinsic Antibiotic Tolerance in Mycobacterium avium.
Matern WM; Parker H; Danchik C; Hoover L; Bader JS; Karakousis PC
Microbiol Spectr; 2021 Oct; 9(2):e0024621. PubMed ID: 34523947
[TBL] [Abstract][Full Text] [Related]
5. Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.
Gebeyehu E; Nigatu D; Engidawork E
PLoS One; 2019; 14(11):e0225585. PubMed ID: 31756217
[TBL] [Abstract][Full Text] [Related]
6. A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.
Schaaf K; Hayley V; Speer A; Wolschendorf F; Niederweis M; Kutsch O; Sun J
Assay Drug Dev Technol; 2016 Aug; 14(6):345-54. PubMed ID: 27327048
[TBL] [Abstract][Full Text] [Related]
7. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.
Gonzalez D; Schmidt S; Derendorf H
Clin Microbiol Rev; 2013 Apr; 26(2):274-88. PubMed ID: 23554417
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.
Dartois V; Barry CE
Curr Clin Pharmacol; 2010 May; 5(2):96-114. PubMed ID: 20156156
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.
Traunmüller F; Zeitlinger M; Zeleny P; Müller M; Joukhadar C
Antimicrob Agents Chemother; 2007 Sep; 51(9):3185-9. PubMed ID: 17606673
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial.
Shi J; Montay G; Bhargava VO
Clin Pharmacokinet; 2005; 44(9):915-34. PubMed ID: 16122280
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Apr; 47(4):1193-9. PubMed ID: 12654646
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of clarithromycin.
Rodvold KA
Clin Pharmacokinet; 1999 Nov; 37(5):385-98. PubMed ID: 10589373
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.
Bergman KL; Olsen KM; Peddicord TE; Fey PD; Rupp ME
Antimicrob Agents Chemother; 1999 May; 43(5):1291-3. PubMed ID: 10223956
[TBL] [Abstract][Full Text] [Related]
14. Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense.
Carlson LD; Wallis CK; Coyle MB
J Clin Microbiol; 1998 Mar; 36(3):748-51. PubMed ID: 9508306
[TBL] [Abstract][Full Text] [Related]
15. Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients.
Langtry HD; Brogden RN
Drugs; 1997 Jun; 53(6):973-1004. PubMed ID: 9179528
[TBL] [Abstract][Full Text] [Related]
16. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.
Rodvold KA; Gotfried MH; Danziger LH; Servi RJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1399-402. PubMed ID: 9174209
[TBL] [Abstract][Full Text] [Related]
17. Antituberculosis activity of clarithromycin.
Luna-Herrera J; Reddy VM; Daneluzzi D; Gangadharam PR
Antimicrob Agents Chemother; 1995 Dec; 39(12):2692-5. PubMed ID: 8593004
[TBL] [Abstract][Full Text] [Related]
18. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.
Conte JE; Golden JA; Duncan S; McKenna E; Zurlinden E
Antimicrob Agents Chemother; 1995 Feb; 39(2):334-8. PubMed ID: 7726492
[TBL] [Abstract][Full Text] [Related]
19. Penetration of clarithromycin into lung tissues from patients undergoing lung resection.
Fish DN; Gotfried MH; Danziger LH; Rodvold KA
Antimicrob Agents Chemother; 1994 Apr; 38(4):876-8. PubMed ID: 8031063
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
